{"FP": [{"generated": ["early in the morning"], "gold": [], "text": "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1)."}, {"generated": ["96 hours"], "gold": [], "text": "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985)."}, {"generated": ["by the time of her presentation"], "gold": [], "text": "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation."}, {"generated": ["30 min"], "gold": [], "text": "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c)."}, {"generated": ["AUC0\u2013\u221e", "", "t1/2"], "gold": [], "text": "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax)."}, {"generated": ["AUC0\u2013\u221e", "", "t1/2"], "gold": [], "text": "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax)."}, {"generated": ["AUC0\u2013\u221e", "", "t1/2"], "gold": [], "text": "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax)."}, {"generated": ["AUC0\u2013\u221e"], "gold": [], "text": "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3."}, {"generated": ["15 minutes", "20 minutes"], "gold": [], "text": "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes."}, {"generated": ["15 minutes", "20 minutes"], "gold": [], "text": "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes."}, {"generated": ["Day 1", "Day 15"], "gold": [], "text": "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3."}, {"generated": ["Day 1", "Day 15"], "gold": [], "text": "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3."}, {"generated": ["1 week", "2 weeks"], "gold": ["for 1 or 2 weeks"], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["1 week", "2 weeks"], "gold": ["for 1 or 2 weeks"], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["2 hours"], "gold": [], "text": "Pharmacokinetic studies started 2 h after the last RGE treatment."}, {"generated": ["3.5 \u03bcm"], "gold": [], "text": "; 3.5\u2009\u03bcm) at room temperature."}, {"generated": ["10 min"], "gold": [], "text": "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis."}, {"generated": ["half-life"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["ventricular fibrillation", "ventricular tachycardia", "QRS interval prolongation", "ventricular precontraction"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["ventricular fibrillation", "ventricular tachycardia", "QRS interval prolongation", "ventricular precontraction"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["ventricular fibrillation", "ventricular tachycardia", "QRS interval prolongation", "ventricular precontraction"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["ventricular fibrillation", "ventricular tachycardia", "QRS interval prolongation", "ventricular precontraction"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["30 minutes"], "gold": ["30-minute"], "text": "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH."}, {"generated": ["24 hours"], "gold": [], "text": "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples)."}, {"generated": ["1 h"], "gold": [], "text": "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide."}, {"generated": ["7 \u00b1 1 days"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["per day"], "gold": [], "text": "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23]."}, {"generated": ["a week", "once daily", "four times daily"], "gold": ["week"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["a week", "once daily", "four times daily"], "gold": ["week"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["a week", "once daily", "four times daily"], "gold": ["week"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["4 times a day", "daily", "once a day"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["4 times a day", "daily", "once a day"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["4 times a day", "daily", "once a day"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["J.-w.C.", "L.T.N.", "Q.T.T.", "H.-y.Y.", "H.-m.B."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["J.-w.C.", "L.T.N.", "Q.T.T.", "H.-y.Y.", "H.-m.B."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["J.-w.C.", "L.T.N.", "Q.T.T.", "H.-y.Y.", "H.-m.B."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["J.-w.C.", "L.T.N.", "Q.T.T.", "H.-y.Y.", "H.-m.B."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["J.-w.C.", "L.T.N.", "Q.T.T.", "H.-y.Y.", "H.-m.B."], "gold": [], "text": "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y."}, {"generated": ["9", "1\u20133", "greater than 65 years of age", "8"], "gold": [], "text": "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age."}, {"generated": ["9", "1\u20133", "greater than 65 years of age", "8"], "gold": [], "text": "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age."}, {"generated": ["9", "1\u20133", "greater than 65 years of age", "8"], "gold": [], "text": "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age."}, {"generated": ["9", "1\u20133", "greater than 65 years of age", "8"], "gold": [], "text": "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age."}, {"generated": ["2 months"], "gold": [], "text": "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy."}, {"generated": ["6 min"], "gold": [], "text": "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min."}, {"generated": ["before and after warfarin dosing"], "gold": [], "text": "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser."}, {"generated": ["investigated", "found", "5 days"], "gold": ["for 5 days"], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": ["investigated", "found", "5 days"], "gold": ["for 5 days"], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": ["investigated", "found", "5 days"], "gold": ["for 5 days"], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": ["30 min", "90 min", "120 min", "24 h", "60 min"], "gold": [], "text": "The authors declare that there is no conflict of interests regarding the publication of this paper."}, {"generated": ["30 min", "90 min", "120 min", "24 h", "60 min"], "gold": [], "text": "The authors declare that there is no conflict of interests regarding the publication of this paper."}, {"generated": ["30 min", "90 min", "120 min", "24 h", "60 min"], "gold": [], "text": "The authors declare that there is no conflict of interests regarding the publication of this paper."}, {"generated": ["30 min", "90 min", "120 min", "24 h", "60 min"], "gold": [], "text": "The authors declare that there is no conflict of interests regarding the publication of this paper."}, {"generated": ["30 min", "90 min", "120 min", "24 h", "60 min"], "gold": [], "text": "The authors declare that there is no conflict of interests regarding the publication of this paper."}, {"generated": ["after venlafaxine discontination"], "gold": [], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": ["hours", "months"], "gold": ["hours to months"], "text": "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation."}, {"generated": ["hours", "months"], "gold": ["hours to months"], "text": "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation."}, {"generated": ["13-fold", "120-fold"], "gold": [], "text": "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24]."}, {"generated": ["13-fold", "120-fold"], "gold": [], "text": "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24]."}, {"generated": ["markedly"], "gold": [], "text": "Furthermore, it decreases insulin and blood glucose markedly [17]."}, {"generated": ["about 4 h"], "gold": [], "text": "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses."}, {"generated": ["dosing interval", "end of dosing interval"], "gold": [], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": ["dosing interval", "end of dosing interval"], "gold": [], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": ["days 14", "days 28", "days 0"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["days 14", "days 28", "days 0"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["days 14", "days 28", "days 0"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["profile", "versus-time", "lists", "after multiple-dose administration"], "gold": [], "text": "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea."}, {"generated": ["profile", "versus-time", "lists", "after multiple-dose administration"], "gold": [], "text": "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea."}, {"generated": ["profile", "versus-time", "lists", "after multiple-dose administration"], "gold": [], "text": "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea."}, {"generated": ["profile", "versus-time", "lists", "after multiple-dose administration"], "gold": [], "text": "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea."}, {"generated": ["8 days", "each", "for 8 days"], "gold": ["for 8\u00a0days"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["8 days", "each", "for 8 days"], "gold": ["for 8\u00a0days"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["8 days", "each", "for 8 days"], "gold": ["for 8\u00a0days"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["12 hours"], "gold": [], "text": "Administration of EGb 761\u00ae 120\u00a0mg b.i.d."}, {"generated": ["1 week"], "gold": ["1\u00a0week"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["37 seconds", "more than 70 seconds"], "gold": [], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": ["37 seconds", "more than 70 seconds"], "gold": [], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": ["12-hour intervals", "3-hour intervals", "4-hour intervals", "6-hour intervals", "10-hour intervals", "8-hour intervals"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["12-hour intervals", "3-hour intervals", "4-hour intervals", "6-hour intervals", "10-hour intervals", "8-hour intervals"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["12-hour intervals", "3-hour intervals", "4-hour intervals", "6-hour intervals", "10-hour intervals", "8-hour intervals"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["12-hour intervals", "3-hour intervals", "4-hour intervals", "6-hour intervals", "10-hour intervals", "8-hour intervals"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["12-hour intervals", "3-hour intervals", "4-hour intervals", "6-hour intervals", "10-hour intervals", "8-hour intervals"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["12-hour intervals", "3-hour intervals", "4-hour intervals", "6-hour intervals", "10-hour intervals", "8-hour intervals"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["four days"], "gold": ["after four days"], "text": "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure."}, {"generated": ["7 days"], "gold": ["for 7 days"], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["2 hours", "7th day"], "gold": ["for 7 days"], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["2 hours", "7th day"], "gold": ["for 7 days"], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["prolonged", "long-term", "chronic"], "gold": [], "text": "and M.A.A."}, {"generated": ["prolonged", "long-term", "chronic"], "gold": [], "text": "and M.A.A."}, {"generated": ["prolonged", "long-term", "chronic"], "gold": [], "text": "and M.A.A."}, {"generated": ["about 20 years"], "gold": [], "text": "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago."}, {"generated": ["duration of antidepressant treatment", "time of immobility", "no specific duration mentioned in given text"], "gold": [], "text": "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test."}, {"generated": ["duration of antidepressant treatment", "time of immobility", "no specific duration mentioned in given text"], "gold": [], "text": "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test."}, {"generated": ["duration of antidepressant treatment", "time of immobility", "no specific duration mentioned in given text"], "gold": [], "text": "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test."}, {"generated": ["greater recovery rate", "throughout the text", "increase in survival", "dose-related or time-dependent", "less decrease"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["greater recovery rate", "throughout the text", "increase in survival", "dose-related or time-dependent", "less decrease"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["greater recovery rate", "throughout the text", "increase in survival", "dose-related or time-dependent", "less decrease"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["greater recovery rate", "throughout the text", "increase in survival", "dose-related or time-dependent", "less decrease"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["greater recovery rate", "throughout the text", "increase in survival", "dose-related or time-dependent", "less decrease"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["30 minutes", "30 seconds"], "gold": [], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": ["30 minutes", "30 seconds"], "gold": [], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": ["daily", "two weeks"], "gold": ["for two weeks"], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": ["daily", "two weeks"], "gold": ["for two weeks"], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": ["1.0 mL", "p.o."], "gold": [], "text": "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)"}, {"generated": ["1.0 mL", "p.o."], "gold": [], "text": "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)"}, {"generated": ["1.56%", "14.38%"], "gold": [], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": ["1.56%", "14.38%"], "gold": [], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": ["seven days"], "gold": [], "text": "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing."}, {"generated": ["0.642min", "0.482min"], "gold": [], "text": "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin)."}, {"generated": ["0.642min", "0.482min"], "gold": [], "text": "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin)."}, {"generated": ["the pharmacokinetic parameters of indomethacin"], "gold": [], "text": "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin."}, {"generated": ["4-5 h", "3-4 h", "2-3 h", "6-7 h", "1-2 h", "0-1 h", "5-6 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4-5 h", "3-4 h", "2-3 h", "6-7 h", "1-2 h", "0-1 h", "5-6 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4-5 h", "3-4 h", "2-3 h", "6-7 h", "1-2 h", "0-1 h", "5-6 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4-5 h", "3-4 h", "2-3 h", "6-7 h", "1-2 h", "0-1 h", "5-6 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4-5 h", "3-4 h", "2-3 h", "6-7 h", "1-2 h", "0-1 h", "5-6 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4-5 h", "3-4 h", "2-3 h", "6-7 h", "1-2 h", "0-1 h", "5-6 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4-5 h", "3-4 h", "2-3 h", "6-7 h", "1-2 h", "0-1 h", "5-6 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["daily", "1.7-2.5 days", "monthly"], "gold": [], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": ["daily", "1.7-2.5 days", "monthly"], "gold": [], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": ["daily", "1.7-2.5 days", "monthly"], "gold": [], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": ["administration", "375 ml"], "gold": [], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": ["administration", "375 ml"], "gold": [], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": ["3 days"], "gold": ["for 3 days"], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": ["15 days"], "gold": ["15 day"], "text": "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18]."}, {"generated": ["10 min", "30 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "15 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["range 4-113 months", "37 months", "mean"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["range 4-113 months", "37 months", "mean"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["range 4-113 months", "37 months", "mean"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["first moment of plasma drug concentration-time curve", "plasma concentration-time curve"], "gold": [], "text": "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve."}, {"generated": ["first moment of plasma drug concentration-time curve", "plasma concentration-time curve"], "gold": [], "text": "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve."}, {"generated": ["five days"], "gold": [], "text": "Five days after presentation, her symptoms had completely resolved."}, {"generated": ["600 \u03bcL", "5 \u03bcL"], "gold": [], "text": "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS."}, {"generated": ["600 \u03bcL", "5 \u03bcL"], "gold": [], "text": "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS."}, {"generated": ["30 min", "Day 5", "following", "8PM dose"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["30 min", "Day 5", "following", "8PM dose"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["30 min", "Day 5", "following", "8PM dose"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["30 min", "Day 5", "following", "8PM dose"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["significant increase", "significant decrease", "reduction"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["significant increase", "significant decrease", "reduction"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["significant increase", "significant decrease", "reduction"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["14-15 min", "0-8.5 min", "11.5-13.5 min", "8.7-11 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["14-15 min", "0-8.5 min", "11.5-13.5 min", "8.7-11 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["14-15 min", "0-8.5 min", "11.5-13.5 min", "8.7-11 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["14-15 min", "0-8.5 min", "11.5-13.5 min", "8.7-11 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["Figure 3"], "gold": [], "text": "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3)."}, {"generated": ["acutely", "12 weeks"], "gold": ["12 weeks"], "text": "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21]."}, {"generated": ["8-114"], "gold": [], "text": "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114]."}, {"generated": ["pretreatment period"], "gold": [], "text": "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect."}, {"generated": ["3 weeks"], "gold": ["after 3 weeks"], "text": "applied atorvastatin in rats after 3 weeks of drinking green tea or water."}], "FN": [{"generated": [], "gold": ["the past two decades"], "text": "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment."}, {"generated": ["1 week", "2 weeks"], "gold": ["for 1 or 2 weeks"], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["30 minutes"], "gold": ["30-minute"], "text": "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH."}, {"generated": [], "gold": ["for 72 h"], "text": "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated."}, {"generated": ["a week", "once daily", "four times daily"], "gold": ["week"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["investigated", "found", "5 days"], "gold": ["for 5 days"], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": [], "gold": ["7 days"], "text": "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively."}, {"generated": ["hours", "months"], "gold": ["hours to months"], "text": "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["women", "within the last year", "within 4\u00a0wk", "more than 10\u00a0h", "within 6\u00a0mo", "within 1\u00a0mo", "within 3\u00a0mo", "after 1\u00a0yr"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["1-week"], "text": "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE)."}, {"generated": [], "gold": ["\u00b11\u00a0day"], "text": "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted."}, {"generated": ["8 days", "each", "for 8 days"], "gold": ["for 8\u00a0days"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["1 week"], "gold": ["1\u00a0week"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": [], "gold": ["8-day period"], "text": "does not affect CYP2C19 activity when administered over an 8-day period."}, {"generated": [], "gold": ["for thousands of years"], "text": "Herbs have been used for primary health care for thousands of years before the advent of modern medicines."}, {"generated": ["four days"], "gold": ["after four days"], "text": "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure."}, {"generated": ["7 days"], "gold": ["for 7 days"], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["2 hours", "7th day"], "gold": ["for 7 days"], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["daily", "two weeks"], "gold": ["for two weeks"], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": ["3 days"], "gold": ["for 3 days"], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": ["15 days"], "gold": ["15 day"], "text": "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18]."}, {"generated": [], "gold": ["30 days"], "text": "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation."}, {"generated": [], "gold": ["14 days"], "text": "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups."}, {"generated": [], "gold": ["for thousands of years"], "text": "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014)."}, {"generated": ["3 weeks"], "gold": ["after 3 weeks"], "text": "applied atorvastatin in rats after 3 weeks of drinking green tea or water."}]}